Top Headlines

PPD hit by higher number of cancellations in Q4

US contract research organisation (CRO) PPD reported a “higher than anticipated” number of cancellations in Q4, bringing to a close 12 months that saw operating income fall 46 per cent to $192m.

Related news

CRL's 2009 preclinical sales slide; but 2010 bookings up

Falling preclinical demand may have dominated Charles River Laboratories’ (CRL) performance in 2009, but stagnant sales from its research models business also failed to impress.

People on the move: pharma outsourcing jobs

Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including a new management team at a NextPharma site and appointments at Quintiles.

FDA: drug safety benefits of import inspection system easy to Predict

The US FDA says its new screening system will expedite the importation of genuine drugs and help inspectors focus their efforts on “high risk” products.

MENA emerging as trial destination says ClinTec CEO

Improving healthcare infrastructure across the region and a large treatment-naïve patient population makes the Middle East and North Africa (MENA) an increasingly attractive destination for drug trials says ClinTec CEO Rabinder Buttar.

News in brief

Today's headlines across the Pharmaceutical industry

News in brief

Berlin Packaging to buy All-Pak from in-PharmaTechnologist.com

Berlin Packaging has agreed to acquire All-Pak, creating a combined company with annual revenues of $500m (€365m) and an expanded geographic, including Puerto Rico.

MDRNA’s formulation stable after 12 months from in-PharmaTechnologist.com

MDRNA’s liposomal drug delivery formulation, DiLA2, lost no potency when stored for 12 months in conditions ranging from -80ºC to 4ºC, helping to validate it for administration of UsiRNA.

Almost half of antimalarials in Senegal are substandard; study from in-PharmaTechnologist.com

Almost half of antimalarials in Senegal are substandard, according to a USP study which will be used by local regulators to focus efforts on high-risk products, brands and geographies.

On your radar